Here’s one of my favourite weekly🧵- by my dear friend BiopharmIQ by Amp - a comprehensive recap which summarises the past week in BioTech. The🧵gathers the best BioTech posts written by some of the best & brightest X’s BioTwitter accounts into one place. IMO a must read! $XBI

Here’s an old CNBC interview of Mammoth Biosciences’s CEO - Trevor Martin in which he discuss Mammoth’s partnership with Bayer AG (‘22) aimed to develop Gene therapies in the liver. I can only assume that Mammoth’s recent $REGN collaboration is relevant to all non-liver targets. $XBI

The most important annual Gene therapy, CRISPR & Gene Editing conference - #ASGCT2024 is coming …If you’re a researcher, a BioTech company or a research institution presenting at #ASGCT24 , I would be happy to prepare a🧵summarising your abstract. Feel free to DM & reach out.

1/WOW! Another huge Pharma & biotech agreement! $REGN & Mammoth Biosciences today announced a collaboration to research, develop & commercialize Mammoth’s in vivo CRISPR Gene Editing therapies for multiple tissues and cell types & Regeneron adeno-associated viral vectors (AAVs). $XBI